Healthcare AI spend hit $3.7 billion, and the deals are all about the clinician's inbox
Healthcare AI spend grew 2.5 times to $3.7 billion, and the week's deals all target the same place: the clinician's working day, from the inbox to the evidence at the point of care.
- Menlo Ventures' 2026 State of AI in Healthcare report says overall spend grew 2.5 times to $3.7 billion, more than the entire vertical AI market a year ago and more than legal and finance combined. Self-reported m:…7527
- Commure acquired Elaborate, a clinical intelligence platform. Patient portal messages per patient rose 153% between 2020 and 2025, and health systems using Elaborate have seen up to 36% less time in the inbox. Self-reported m:…9685
- Wiley will license the Cochrane Database of Systematic Reviews and Cochrane Clinical Answers to Abridge. Abridge says it is used across more than 300 US health systems and will support more than 120 million patient encounters this year. Self-reported m:…1995
- Every Cure and OpenEvidence partnered to repurpose existing medicines for patients who have run out of options, building on more than 3,000 expert-reviewed rare disease summaries developed with the National Organization for Rare Disorders. Self-reported m:…6663
- Viz.ai and Wolters Kluwer will integrate UpToDate Expert AI into the Viz.ai One platform. Viz.ai says it is used in 2,000 US hospitals and has expanded to more than 50 AI-powered care pathways. Self-reported m:…7660
The money moved closer to the patient
Healthcare AI spending is no longer a promise. Menlo Ventures' 2026 State of AI in Healthcare report says overall spend grew 2.5 times to $3.7 billion, more than the entire vertical AI market a year ago, which Menlo puts at $3.5 billion, and more than legal and finance combined. The report says healthcare AI accelerated in life sciences in 2026 and moved closer to the patient. That is the context for a cluster of deals announced on November 16, all aimed at the same place: the clinician's working day. m:…7527
The inbox is the acquisition
The clearest of them is Commure's acquisition of Elaborate, a clinical intelligence platform the company describes as curing the inbox. Patient portal messages per patient rose 153% between 2020 and 2025, according to Commure, and health systems using Elaborate have seen up to 36% less time in the inbox, with a 15% reduction in patient message volumes and 97% clinician alignment with automation. Commure says its agents already handle intake, work the phones, write the note, code the claim and handle denials, and that it is live in more than 500 healthcare organisations with more than 500,000 users, with 7% of American healthcare appointments running through it. The acquisition is a bet that the inbox, not the diagnosis, is where AI earns its keep in healthcare. m:…9685
Evidence at the point of care
Two partnerships make the same bet from the evidence side. Wiley and Abridge announced a multi-year partnership under which Wiley will license the Cochrane Database of Systematic Reviews and Cochrane Clinical Answers to Abridge, for integration into the Abridge Assistant as concise, cited summaries. Abridge says it is used across more than 300 US health systems and will support more than 120 million patient encounters this year. Separately, Viz.ai and Wolters Kluwer said they will integrate UpToDate Expert AI into the Viz.ai One platform, putting evidence authored and regularly updated by more than 7,600 physician authors, editors and peer reviewers in front of specialists at the point of care. Viz.ai says it is used in 2,000 US hospitals and has expanded to more than 50 AI-powered care pathways. m:…1995 m:…7660
Repurposing where the market will not go
A fifth deal points at a different corner of the same workflow. Every Cure, a nonprofit focused on drug repurposing, announced a partnership with OpenEvidence to turn existing medicines into new treatments for patients who have run out of options. OpenEvidence will help Every Cure evaluate therapeutic hypotheses, match patients to trials and disseminate evidence at the point of care. The partnership builds on more than 3,000 expert-reviewed rare disease summaries developed with the National Organization for Rare Disorders. OpenEvidence says it is the medical AI platform used daily, on average, by the majority of physicians in the United States, and that it will match Every Cure's repurposing programs with the clinicians who can bring these insights into research. The deal is a reminder that the workflow story is not only about saving clinicians time. It is also about reaching patients the commercial market has passed over. m:…6663
What the buyer should ask
None of these deals is about a new model. They are about distribution into workflows clinicians already use: the inbox, the note, the care pathway. That is also the risk. The numbers in each announcement come from the companies themselves, inbox time saved, encounters supported, hospitals reached, and none of them is an independent measure of patient outcomes. For a health-system executive, the decision is straightforward to frame and hard to make: buy the workflow that removes work from clinicians today, and demand outcome data before renewing. The money has already made its choice. It is flowing to the companies that sit closest to the clinician. m:…9685 m:…1995 m:…7660
What is still unresolved
- The price Commure paid for Elaborate was not disclosed in the announcement.
- No independent patient-outcome data was published with any of the four announcements.
- Whether inbox-time savings hold up across health systems that were not early Elaborate users.
- Whether OpenEvidence's reach among physicians translates into faster recruitment for Every Cure's repurposing trials.
Provenance by Synorb. Every claim links to its source. This story was written by an agent from the Manifests listed below. Read the methodology and limitations, or send a correction.
Free to reuse, including commercially. Credit “Hanging Context, with provenance by Synorb” and link to this story. Keep the cited Manifest ids. Reuse terms v1.